Trial · NCT02418000
Results by group101
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 101
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of E6201 | All Participants | 320 | E6201 MTD (mg/m^2) IV twice weekly | ||
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | E6201 240 mg/m^2 Weekly | 1 | Number of Participants with DLTs | ||
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | E6201 320 mg/m^2 Weekly | 1 | Number of Participants with DLTs | ||
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | E6201 160 mg/m^2 Twice Weekly | 0 | Number of Participants with DLTs | ||
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | E6201 240 mg/m^2 Twice Weekly | 0 | Number of Participants with DLTs | ||
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | E6201 320 mg/m^2 IV Twice Weekly | 0 | Number of Participants with DLTs | ||
| Overall Response Rate | E6201 240 mg/m^2 Weekly | 0 | Objective Responses | ||
| Overall Response Rate | E6201 320 mg/m^2 Weekly | 0 | Objective Responses | ||
| Overall Response Rate | E6201 160 mg/m^2 Twice Weekly | 0 | Objective Responses | ||
| Overall Response Rate | E6201 240 mg/m^2 Twice Weekly | 0 | Objective Responses | ||
| Overall Response Rate | E6201 320 mg/m^2 Twice Weekly | 0 | Objective Responses | ||
| Overall Survival | E6201 240 mg/m^2 Weekly | 31 | Standard Deviation 13.01 | Days | |
| Overall Survival | E6201 320 mg/m^2 Weekly | 68 | Standard Deviation 50.39 | Days | |
| Overall Survival | E6201 160 mg/m^2 Twice Weekly | 96 | Standard Deviation 69.30 | Days | |
| Overall Survival | E6201 240 mg/m^2 Twice Weekly | 99 | Standard Deviation 48.08 | Days | |
| Overall Survival | E6201 320 mg/m^2 Twice Weekly | 30 | Standard Deviation 35.37 | Days | |
| Pharmacokinetic Profile of E6201 in Plasma: Cmax | E6201 240 mg/m^2 Weekly | 1195.04 | Standard Deviation 10.6 | ng/mL | |
| Pharmacokinetic Profile of E6201 in Plasma: Cmax | E6201 320 mg/m^2 Weekly | 1430.39 | Standard Deviation 76.2 | ng/mL | |
| Pharmacokinetic Profile of E6201 in Plasma: Cmax | E6201 160 mg/m^2 Twice Weekly | 736.87 | Standard Deviation 50.7 | ng/mL | |
| Pharmacokinetic Profile of E6201 in Plasma: Cmax | E6201 240 mg/m^2 Twice Weekly | 941.66 | Standard Deviation 47.7 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02418000/results